AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivashchenko, Andrey A, Dmitriev, Kirill A, Vostokova, Natalia V, Azarova, Valeria N, Blinow, Andrew A, Egorova, Alina N, Gordeev, Ivan G, Ilin, Alexey P, Karapetian, Ruben N, Kravchenko, Dmitry V, Lomakin, Nikita V, Merkulova, Elena A, Papazova, Natalia A, Pavlikova, Elena P, Savchuk, Nikolay P, Simakina, Elena N, Sitdekov, Tagir A, Smolyarchuk, Elena A, Tikhomolova, Elena G, Yakubova, Elena V, Ivachtchenko, Alexandre V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454388/
https://www.ncbi.nlm.nih.gov/pubmed/32770240
http://dx.doi.org/10.1093/cid/ciaa1176

Ejemplares similares

Ejemplares similares